ATTEST

AstraZeneca - ATTEST

Association of the risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 vaccines

Aims

To evaluate an association between COVID19 vaccine exposure and thromboembolic events occurring with thrombocytopenia (thrombotic thrombocytopenia syndrome; TTS).

Deliverables

Report to regulators and scientific publications.

Expected Impact

The project will shed more light on the safety of the AstraZeneca and Pfizer COVID-19 vaccines.

Project outline

This project will investigate the risk of thrombotic thrombocytopenia syndrome (TTS), a rare condition involving both blood clots and low platelet counts, following COVID-19 vaccination with AZD1222 (Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech).

How does this research try to address the problem?

Using the ORCHID RCGP RSC primary care data linked to national secondary care hospital admissions, ONS mortality, vaccination and testing data, we will design a matched case-control study and a self-controlled case series to learn about the safety of the AstraZeneca and Pfizer vaccines.

How we are planning to implement the research outputs

The findings of these analyses will be compiled in a report to the regulators and various scientific publications.